JHL Biotech, Inc. announced that the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved JHL's Phase I and Phase III Clinical Trial Application for a proposed rituximab biosimilar, JHL1101, to treat non-Hodgkin lymphoma. JHL will begin clinical trials of JHL1101 in the following months.